Cargando…

Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease

HIGHLIGHTS: ASS234 is a MTDL compound containing a moiety from Donepezil and the propargyl group from the PF 9601N, a potent and selective MAO B inhibitor. This compound is the most advanced anti-Alzheimer agent for preclinical studies identified in our laboratory. Derived from ASS234 both multipote...

Descripción completa

Detalles Bibliográficos
Autores principales:	Unzeta, Mercedes, Esteban, Gerard, Bolea, Irene, Fogel, Wieslawa A., Ramsay, Rona R., Youdim, Moussa B. H., Tipton, Keith F., Marco-Contelles, José
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879129/ https://www.ncbi.nlm.nih.gov/pubmed/27252617 http://dx.doi.org/10.3389/fnins.2016.00205

Ejemplares similares

ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy
por: Marco-Contelles, José, et al.
Publicado: (2016)

Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer’s disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids
por: Bautista-Aguilera, Oscar M, et al.
Publicado: (2014)

Novel Donepezil–Arylsulfonamide Hybrids as Multitarget-Directed Ligands for Potential Treatment of Alzheimer’s Disease
por: Queda, Fausto, et al.
Publicado: (2021)

Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer’s disease therapy
por: Pachón-Angona, Irene, et al.
Publicado: (2019)

Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases
por: Di Giovanni, Giuseppe, et al.
Publicado: (2016)

One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug
por: Hughes, Rebecca E., et al.
Publicado: (2016)

Design, synthesis, and evaluation of chalcone-Vitamin E-donepezil hybrids as multi-target-directed ligands for the treatment of Alzheimer’s disease
por: Sang, Zhipei, et al.
Publicado: (2021)

Design, Synthesis, and In Vitro Evaluation of Hydroxybenzimidazole-Donepezil Analogues as Multitarget-Directed Ligands for the Treatment of Alzheimer’s Disease
por: Chaves, Sílvia, et al.
Publicado: (2020)

Gene Polymorphisms Affecting the Pharmacokinetics and Pharmacodynamics of Donepezil Efficacy
por: Lu, Jin, et al.
Publicado: (2020)

Regional siderosis: a new challenge for iron chelation therapy
por: Cabantchik, Zvi Ioav, et al.
Publicado: (2013)

PQM130, a Novel Feruloyl–Donepezil Hybrid Compound, Effectively Ameliorates the Cognitive Impairments and Pathology in a Mouse Model of Alzheimer’s Disease
por: Morroni, Fabiana, et al.
Publicado: (2019)

Multi Target Neuroprotective and Neurorestorative Anti-Parkinson and Anti-Alzheimer Drugs Ladostigil and M30 Derived from Rasagiline
por: Youdim, Moussa B.H.
Publicado: (2013)

Transdermal donepezil on the treatment of Alzheimer’s disease
por: Sozio, Piera, et al.
Publicado: (2012)

The Neuroprotective Activities of the Novel Multi-Target Iron-Chelators in Models of Alzheimer’s Disease, Amyotrophic Lateral Sclerosis and Aging
por: Kupershmidt, Lana, et al.
Publicado: (2023)

New Approaches to Treating Alzheimer’s Disease
por: Zheng, Hailin, et al.
Publicado: (2015)

Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson’s and Alzheimer’s Disorders?
por: Youdim, Moussa B. H.
Publicado: (2010)

Pharmacotherapy of Traumatic Childhood Aphasia: Beneficial Effects of Donepezil Alone and Combined With Intensive Naming Therapy
por: Dávila, Guadalupe, et al.
Publicado: (2020)

Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases
por: Pooladgar, Parham, et al.
Publicado: (2022)

Advances in Multi-Functional Ligands and the Need for Metal-Related Pharmacology for the Management of Alzheimer Disease
por: Sharma, Abha, et al.
Publicado: (2018)

Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson's and Alzheimer's Diseases as Disease Modifying Agents
por: Youdim, Moussa B. H.
Publicado: (2010)

From Single Target to Multitarget/Network Therapeutics in Alzheimer’s Therapy
por: Zheng, Hailin, et al.
Publicado: (2014)

Editorial: Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases
por: Ramsay, Rona R., et al.
Publicado: (2017)

Ginkgo Biloba Extract Is Comparable With Donepezil in Improving Functional Recovery in Alzheimer’s Disease: Results From a Multilevel Characterized Study Based on Clinical Features and Resting-State Functional Magnetic Resonance Imaging
por: Zheng, Yu, et al.
Publicado: (2021)

SSAO/VAP-1 in Cerebrovascular Disorders: A Potential Therapeutic Target for Stroke and Alzheimer’s Disease
por: Unzeta, Mercedes, et al.
Publicado: (2021)

Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics
por: Cacabelos, Ramón
Publicado: (2007)

Donepezil enhances understanding of degraded speech in Alzheimer's disease
por: Hardy, Chris J. D., et al.
Publicado: (2017)

Donepezil Treatment for Alzheimer's Disease in Chronic Dialysis Patients
por: Yiannopoulou, Konstantina G., et al.
Publicado: (2019)

The effect of funding sources on donepezil randomised controlled trial outcome: a meta-analysis
por: Killin, Lewis O J, et al.
Publicado: (2014)

Neuroprotection and Neuroregeneration in Alzheimer's Disease
por: Sugaya, Kiminobu, et al.
Publicado: (2012)

APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer’s Disease
por: Waring, Jeffrey F., et al.
Publicado: (2015)

From tryptamine to the discovery of efficient multi-target directed ligands against cholinesterase-associated neurodegenerative disorders
por: Wu, Junbo, et al.
Publicado: (2022)

Comparison of Donepezil, Memantine, Melatonin, and Liuwei Dihuang Decoction on Behavioral and Immune Endocrine Responses of Aged Senescence-Accelerated Mouse Resistant 1 Mice
por: Zeng, Ju, et al.
Publicado: (2020)

Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs
por: Ramsay, Rona R., et al.
Publicado: (2017)

Studies on Interaction of Buffalo Brain Cystatin with Donepezil: An Alzheimer's Drug
por: Amin, Fakhra, et al.
Publicado: (2013)

Effect of donepezil on transcranial magnetic stimulation parameters in Alzheimer's disease
por: Hwang, Yun Tae, et al.
Publicado: (2018)

Commentary: Donepezil enhances understanding of degraded speech in Alzheimer's disease
por: Campbell, Tom A., et al.
Publicado: (2018)

Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer’s Disease
por: Chase, Thomas N., et al.
Publicado: (2017)

The Serotonin Receptor 6 Antagonist Idalopirdine and Acetylcholinesterase Inhibitor Donepezil Have Synergistic Effects on Brain Activity—A Functional MRI Study in the Awake Rat
por: Ferris, Craig F., et al.
Publicado: (2017)

Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration
por: Ramsay, Rona R., et al.
Publicado: (2016)

The Synergistic Enhancing-Memory Effect of Donepezil and S 38093 (a Histamine H(3) Antagonist) Is Mediated by Increased Neural Activity in the Septo-hippocampal Circuitry in Middle-Aged Mice
por: Sors, Aurore, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_osk0ptogqm5vs1au2ernl1sr19